http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전이성 전립선암 환자에서 항남성 호르몬 요법의 예후 인자 비교
김정만,이창렬,하홍구,이완,정문기 부산대학교 병원 암연구소 2006 부산대병원학술지 Vol.- No.20
Purpose: The prognostic factors in patients with metastatic prostate cancer after androgen deprivation treatment was assessed retrospectively. Subject and Methods: Seventy patients with metastatic prostatic cancer treated with androgen deprivation therapy were included in this study. Variety of possible prognostic factors, such as age, pretreatment serum prostate specific antigen (PSA), Gleason score, value of nadir serum PSA, duration to nadir serum PSA and treatment modality were analyzed. Results: Median age of patients was 70.5 (56-90) years and 16 patients were expired, who's median survival time was 27.2 (6-97) months and median survival time of patients who are alive was 27.6 (3-82) months. Median survival time of pretreatment serum PSA level of 0-9.99 ng/ml, 10-99.99 ng/ml, 100-499.99 ng/ml and >500 ng/ml was 42.0, 23, 19 and 15 months, repectively (p=0.019). Median survival time of nadir serum PSA of 0-0.2 ng/ml, 0.21-4 ng/ml and >4 ng/ml was 22.5, 19.5 and 16 months, repectively (p<0.0001). Median survival time of monotherapy and combination therapy was 23 and 19 months, respectively (p=0.035). But age, gleason score and duration to nadir serum PSA did not relate significantly with survival. Conclusion: The results of present study suggest that pretreatment serum PSA, the value of nadir serum PSA and treatment modality are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with androgen deprivation therapy.